Deprescribing Interventions in Older Adults with Polypharmacy: A Systematic Review of Economic Evaluations.

In 30 seconds

This systematic review evaluated the economic evidence of deprescribing interventions in older adults (≥65 years) with polypharmacy. It found that deprescribing high-risk medications, such as sedatives and proton pump inhibitors, is often cost-saving, primarily due to reduced adverse drug events. The review included eight studies, with two being trial-based.

Key findings

• Deprescribing high-risk medications was often cost-saving or dominant.
• Structured, multi-component approaches showed greater effectiveness in economic outcomes.
• Evidence for antihypertensive deprescribing was limited and context-dependent.
• Quality assessment revealed gaps in uncertainty handling and reporting transparency.

Why it matters

Understanding the economic implications of deprescribing can help clinicians make informed decisions about medication management in older adults, potentially reducing medication-related harm and healthcare costs.